🌈 breaking ranks.1/2
"#Lenacapavir, a twice-yearly, long-acting #HIV prevention tool, represents one of the most promising advances towards ending #AIDS [.]. #Gilead has an obligation to ensure that access is not restricted by where people live, who they are, or what their country can pay. [.] this drug’s development was supported by public funding and through the trust of communities who participated in clinical trials, many of them in countries now excluded from affordable access [.]."
2/2
"We call on #Gilead to respond by April 13, 2026 clarifying:
1. Whether you will sell #lenacapavir directly to #MSF?
2. If not, why, given your stated production capacity?
3. If yes, at what price and how soon can delivery begin?
The #health of many people depends on your answers to these questions."
Via @sham |s faboulous newsletter what happened last week in Asia, Africa and the Americas.